Emerging issues in the management of infections caused by multi-drug-resistant, gram-negative bacilli.

摘要: BACKGROUND The past decade has witnessed the continued emergence and spread of multidrug resistance in gram-negative bacilli. Infections caused by multi-drug-resistant, bacilli lead, many instances, to increased morbidity mortality, prolonged hospital stays, use broad-spectrum antibiotics. METHODS Recent literature from 1990 present is reviewed order put into perspective effects increasing incidences multi-drug-resistant on patient care. RESULTS Factors important include severity illness hospitalized patients, poor attention infection control practices healthcare personnel, large, often indiscriminate antimicrobial agents. Unlike earlier iterations, there no steady stream newer agents development address problem. only agent with activity against multi-resistant, potential be licensed foreseeable future tigecycline. Tigecycline, first member a novel class antimicrobials, glycylcyclines, structural derivative minocycline, potent most gram-positive, (excepting Pseudomonas aeruginosa Proteus spp.) anaerobic species. Phase 3 trials indicate that tigecycline effective for treating both complicated skin structure infections, intra-abdominal infections patients. CONCLUSION Tigecycline promises an addition our monotherapy armamentarium, complementing essential efforts promote compliance good measures rational currently available